EGFR and non-small cell lung carcinoma: Prospective clinical trials of EGFR-TKI treatment for NSCLC patients with activating EGFR mutations, such as delE746-A750 (exon 19) and L858R (exon 21), have demonstrated high clinical response rates of approximately 80% [4]–[7].